NEW DELHI, October 22 — The Department of Pharmaceuticals, under the Ministry of Chemicals and Fertilizers, sanctioned the inaugural tranche of collaborative research grants on Wednesday under the ₹5,000 Crore 'Promotion of Research and Innovation in Pharma-MedTech Sector' (PRIP) scheme.
Structured to pivot India’s pharmaceutical industry from volume-led off-patent generics toward high-value novel drug discovery, Component-A of the scheme operationalizes seven specialized Centres of Excellence across National Institutes of Pharmaceutical Education and Research (NIPERs) with an outlay of ₹700 Crore. Component-B earmarks ₹4,250 Crore in direct financial incentives for private industries and startups developing New Chemical Entities (NCEs), precision biologics, biosimilars, and orphan drugs for rare diseases.
Complementing the funding architecture, the government scaled the 'MedTech Mitra' strategic handholding portal—jointly run by NITI Aayog, ICMR, and CDSCO—assisting indigenous biomedical engineers with clinical trial protocols and regulatory compliance for complex radiology and diagnostic hardware.
India's position as the largest global provider of generic medicines by volume (20% of global supply), the Production Linked Incentive (PLI) scheme for Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs) to curb import dependence, and NIPER governance are key syllabus themes in UPSC GS-III.